FDA Approps Amendment Targets Chief Counsel Troy
This article was originally published in The Gray Sheet
Executive Summary
FDA Chief Counsel Daniel Troy's intervention in civil suits on behalf of device maker Pacesetter and several drug firms has drawn a rebuke from House legislators in the form of funding cuts
You may also be interested in...
User Fee Revenue Sums Would Be Unknown By FDA Under House Proposal
A FDL-1bill pending in the House Energy & Commerce Committee would allocate all FDA user fee revenue to a general Treasury fund
User Fee Revenue Sums Would Be Unknown By FDA Under House Proposal
A FDL-1bill pending in the House Energy & Commerce Committee would allocate all FDA user fee revenue to a general Treasury fund
Preemption Redemption: FDA Legal Briefs Stand In For Product Liability Law
FDA's new-found willingness to invoke the federal preemption doctrine in state tort suits may provide device firms with some solace in the absence of product liability reform legislation, but prospects remain unclear for non-original-PMA devices